Jun 16, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
FDA: New Warnings Required On Use Of Gadolinium-Based Contrast Agents
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2301620" data-attributes="member: 124445"><p>The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis (NSF), if the drug is administered to certain patients with kidney disease. Three of the GBCAs - Magnevist, Omniscan, and Optimark - will be described as inappropriate for use among patients with acute kidney injury or chronic severe kidney disease... <a href="http://feedads.g.doubleclick.net/~a/BG2xOYnpyxGqkJRW6JQwe2E2i4o/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/BG2xOYnpyxGqkJRW6JQwe2E2i4o/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/BG2xOYnpyxGqkJRW6JQwe2E2i4o/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/BG2xOYnpyxGqkJRW6JQwe2E2i4o/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/MfkLRz1zboI" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/MfkLRz1zboI/3JB3" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2301620, member: 124445"] The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis (NSF), if the drug is administered to certain patients with kidney disease. Three of the GBCAs - Magnevist, Omniscan, and Optimark - will be described as inappropriate for use among patients with acute kidney injury or chronic severe kidney disease... [URL="http://feedads.g.doubleclick.net/~a/BG2xOYnpyxGqkJRW6JQwe2E2i4o/0/da"][IMG]http://feedads.g.doubleclick.net/~a/BG2xOYnpyxGqkJRW6JQwe2E2i4o/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/BG2xOYnpyxGqkJRW6JQwe2E2i4o/1/da"][IMG]http://feedads.g.doubleclick.net/~a/BG2xOYnpyxGqkJRW6JQwe2E2i4o/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/MfkLRz1zboI[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/MfkLRz1zboI/3JB3]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top